Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Neuronetics ( (STIM) ).
On May 6, 2025, Neuronetics announced the upcoming retirement of CFO Stephen Furlong in March 2026, with a search for his successor underway. The company reported significant financial growth in the first quarter of 2025, with an 84% revenue increase driven by the Greenbrook acquisition. Neuronetics also highlighted major insurance coverage expansions for adolescent TMS treatment and projected achieving positive cash flow in the third quarter of 2025.
Spark’s Take on STIM Stock
According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.
Neuronetics’ stock faces significant financial challenges, with ongoing losses and cash flow difficulties. While strategic acquisitions and revenue growth provide some optimism, the company’s high leverage and negative valuation metrics weigh heavily on its overall outlook. Technical indicators are mixed, and recent corporate events suggest potential for future improvement, but substantial risks remain.
To see Spark’s full report on STIM stock, click here.
More about Neuronetics
Neuronetics, Inc. is a vertically integrated, commercial stage medical technology and healthcare company focused on transforming the lives of patients with leading neurohealth therapies. The company is known for its NeuroStar Advanced Therapy System, which is used for mental health treatments.
YTD Price Performance: 202.01%
Average Trading Volume: 1,461,909
Technical Sentiment Signal: Sell
Current Market Cap: $301.4M
For an in-depth examination of STIM stock, go to TipRanks’ Stock Analysis page.